Profund Advisors LLC Has $1.26 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX

Profund Advisors LLC boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 94.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,038 shares of the company’s stock after acquiring an additional 29,221 shares during the period. Profund Advisors LLC owned 0.07% of Syndax Pharmaceuticals worth $1,261,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNDX. Vanguard Group Inc. lifted its position in Syndax Pharmaceuticals by 21.2% during the 4th quarter. Vanguard Group Inc. now owns 6,230,334 shares of the company’s stock valued at $130,899,000 after purchasing an additional 1,091,717 shares during the period. Bank of America Corp DE grew its position in shares of Syndax Pharmaceuticals by 33.7% during the 2nd quarter. Bank of America Corp DE now owns 3,838,872 shares of the company’s stock worth $35,951,000 after buying an additional 967,873 shares during the period. Qube Research & Technologies Ltd raised its stake in shares of Syndax Pharmaceuticals by 99.5% during the second quarter. Qube Research & Technologies Ltd now owns 1,665,916 shares of the company’s stock worth $15,601,000 after buying an additional 831,067 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Syndax Pharmaceuticals by 126.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,432,440 shares of the company’s stock worth $13,415,000 after buying an additional 800,800 shares during the last quarter. Finally, Apis Capital Advisors LLC acquired a new position in Syndax Pharmaceuticals in the third quarter valued at approximately $9,816,000.

Syndax Pharmaceuticals Stock Up 4.0%

Shares of NASDAQ SNDX opened at $20.13 on Thursday. The stock has a market cap of $1.78 billion, a P/E ratio of -7.22 and a beta of 0.41. The firm has a 50 day moving average price of $22.82 and a 200 day moving average price of $20.94. The company has a debt-to-equity ratio of 8.26, a quick ratio of 5.06 and a current ratio of 5.47. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.59 and a 52-week high of $25.59.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.11. The company had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. The business’s revenue for the quarter was up 224.3% compared to the same quarter last year. During the same period last year, the business posted ($0.98) earnings per share. Analysts expect that Syndax Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on SNDX shares. UBS Group lowered their target price on shares of Syndax Pharmaceuticals from $38.00 to $37.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Wall Street Zen raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. JPMorgan Chase & Co. raised their price target on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an “overweight” rating in a research report on Monday, March 9th. Mizuho decreased their price objective on Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price objective (down from $48.00) on shares of Syndax Pharmaceuticals in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.55.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.